Breaking News

Genmab Achieves Janssen Milestone

March 9, 2016

Advances Phase II trial in follicular lymphoma

Genmab has reached a $5 million milestone in its daratumumab collaboration with Janssen Biotech triggered by progress in the ongoing Phase II study ("Carina" LYM2001) in NHL.
 
The study evaluates daratumumab monotherapy in three different types of NHL, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL). This milestone is related to progress in the arm of the study treating patients with FL.
 
"The daratumumab study in NHL is now underway, and we are very pleased to have achieved milestones for progress in two of the disease areas included in the study, FL and DLBCL," said Jan van de Winkel, Ph.D., chief executive officer of Genmab. "We remain optimistic about the therapeutic potential of daratumumab in indications outside of multiple myeloma."
 
Daratumumab has received Orphan Drug designation from the FDA for DLBCL, MCL and FL.
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems